BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 31808941)

  • 1. Checkpoint inhibitors in AML: are we there yet?
    Ghosh A; Barba P; Perales MA
    Br J Haematol; 2020 Jan; 188(1):159-167. PubMed ID: 31808941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors.
    Hui E
    J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in hematologic malignancies: past, present, and future.
    Im A; Pavletic SZ
    J Hematol Oncol; 2017 Apr; 10(1):94. PubMed ID: 28434396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.
    Assi R; Kantarjian H; Ravandi F; Daver N
    Curr Opin Hematol; 2018 Mar; 25(2):136-145. PubMed ID: 29206680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint inhibitors in hematological malignancies.
    Ok CY; Young KH
    J Hematol Oncol; 2017 May; 10(1):103. PubMed ID: 28482851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for checkpoint inhibition in hematologic malignancies.
    Atanackovic D; Luetkens T
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy Toxicity.
    Mantia CM; Buchbinder EI
    Hematol Oncol Clin North Am; 2019 Apr; 33(2):275-290. PubMed ID: 30833000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune-checkpoint and hemopathies].
    Burroni B; Broudin C; Damotte D; Laurent C
    Ann Pathol; 2017 Feb; 37(1):101-110. PubMed ID: 28161001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in genitourinary malignancies.
    Mehta K; Patel K; Parikh RA
    J Hematol Oncol; 2017 Apr; 10(1):95. PubMed ID: 28434403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 20. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
    Sehgal A; Whiteside TL; Boyiadzis M
    Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.